Physician profile
Gregory A King
NPI 1780687269
$2,512.04
in general payments reported to CMS, 2019-2025
18 companies · $318 in 2025
The $318 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $563 · 2020: $120 · 2021: $545 · 2022: $355 · 2023: $268 · 2024: $342 · 2025: $318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $928.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $928.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $899.83 | 2019-2025 | Clareon, Rocklatan, Tryptyr |
| Sun Pharmaceutical Industries INC. | $269.80 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $255.35 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $171.84 | 2022-2025 | Vyzulta, Envista Mx60 Iol, Miebo |
| Sight Sciences, INC. | $161.49 | 2024-2025 | Omni Surgical System, Sion Surgical Instrument |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $133.81 | 2019-2021 | |
| Shire North American Group INC | $122.72 | 2019 | |
| Abbvie INC. | $109.18 | 2023-2025 | |
| Allergan, INC. | $81.47 | 2020-2022 | |
| Rxsight INC | $77.73 | 2023-2024 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Injector Handpiece |
| Rayner Intraocular Lenses Limited | $77.07 | 2022-2024 | Omidria, Rayone Spheric, Rayone Aspheric |
| Amgen INC. | $34.76 | 2024 | Tepezza |
| Omeros Corporation | $31.08 | 2020-2021 | |
| Oyster Point Pharma, INC. | $19.92 | 2025 | Ryzumvi, Tyrvaya |
| Eyevance Pharmaceuticals LLC | $19.15 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Notal Vision, INC. | $16.40 | 2025 | Foresee Home |
| Tarsus Pharmaceuticals, INC. | $15.37 | 2024 | Xdemvy |
| Horizon Therapeutics Plc | $15.07 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.